X4 Pharmaceuticals Faces Delisting Concerns
Ticker: XFOR · Form: 8-K · Filed: Aug 16, 2024 · CIK: 1501697
| Field | Detail |
|---|---|
| Company | X4 Pharmaceuticals, Inc (XFOR) |
| Form Type | 8-K |
| Filed Date | Aug 16, 2024 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, biotech
TL;DR
X4 Pharma's on the chopping block - might get delisted.
AI Summary
X4 Pharmaceuticals, Inc. filed an 8-K on August 16, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, formerly known as Arsanis, Inc., is based in Boston, MA, and operates in the biological products sector.
Why It Matters
This filing indicates potential issues with X4 Pharmaceuticals' continued listing on a stock exchange, which could significantly impact its stock value and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.
Key Numbers
- 001-38295 — Commission File Number (Identifies the company's SEC filing history.)
- 27-3181608 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- X4 Pharmaceuticals, Inc. (company) — Registrant
- Arsanis, Inc. (company) — Former company name
- August 13, 2024 (date) — Earliest event reported
- August 16, 2024 (date) — Date of report
- 61 North Beacon Street, 4th Floor Boston, Massachusetts 02134 (address) — Principal executive offices
FAQ
What specific listing rule or standard has X4 Pharmaceuticals failed to satisfy?
The filing does not specify the exact rule or standard that X4 Pharmaceuticals has failed to satisfy, only that a notice has been issued.
What is the expected timeline for the delisting process?
The filing does not provide a specific timeline for the delisting process.
Has X4 Pharmaceuticals taken any steps to address the listing deficiency?
The filing does not detail any specific actions taken by X4 Pharmaceuticals to address the listing deficiency.
What is the significance of the former company name 'Arsanis, Inc.'?
The company was formerly known as Arsanis, Inc., with a name change date of September 20, 2010.
Where are X4 Pharmaceuticals' principal executive offices located?
The principal executive offices are located at 61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134.
Filing Stats: 858 words · 3 min read · ~3 pages · Grade level 14.7 · Accepted 2024-08-16 16:03:56
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share XFOR The Nasdaq Stock Market
- $1.00 — required closing bid price of at least $1.00 per share, as required for continued li
Filing Documents
- xfor-20240813.htm (8-K) — 28KB
- 0001628280-24-037546.txt ( ) — 155KB
- xfor-20240813.xsd (EX-101.SCH) — 2KB
- xfor-20240813_lab.xml (EX-101.LAB) — 23KB
- xfor-20240813_pre.xml (EX-101.PRE) — 13KB
- xfor-20240813_htm.xml (XML) — 3KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On August 13, 2024, X4 Pharmaceuticals, Inc. (the "Company") received a deficiency letter (the "Nasdaq Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, for the last 32 consecutive business days, the closing bid price of the Company's shares of common stock, $0.001 par value per share ("Common Stock"), has not been maintained at the minimum required closing bid price of at least $1.00 per share, as required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). The Nasdaq Letter does not result in the immediate delisting of the Company's Common Stock, and the Company's Common Stock will continue to trade uninterrupted on the Nasdaq Capital Market under the symbol "XFOR." In accordance with the listing rules of Nasdaq, the Company has been given 180 calendar days, or until February 10, 2025 (the "Compliance Date"), to regain compliance with the minimum bid price requirement. If at any time before the Compliance Date, the closing bid price of the Company's Common Stock is at least $1.00 per share for a minimum of ten consecutive business days, Nasdaq will provide written notification to the Company that it complies with the minimum bid price requirement. If the Company is unable to regain compliance before the Compliance Date, the Company may be eligible for an additional 180 calendar days to satisfy the Bid Price Rule. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market with the exception of the Bid Price Rule, and will need to provide written notice of its intention to cure the deficiency during such additional compliance period, by effecting a reverse stock split, if necessary. If it appears to Nasdaq staff that the Com
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. X4 PHARMACEUTICALS, INC. Date: August 16, 2024 By: /s/ Adam Mostafa Adam Mostafa Chief Financial Officer